For instance, selective TRPA1 agonists (e.g., brain tumors) or blockers (e.g., lung and breast cancers) could be administered as adjuvant drugs of ROS-producing therapeutics, such as carboplatin, doxorubicin, and paclitaxel, to increase cancer cell sensitivity to oxidative stress. This evidence concerns the gene TRPA1 and cancer.